Provention Bio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2016-10-04
- Employees
- 174
- Market Cap
- -
- Website
- http://www.proventionbio.com
PROtocol for Coxsackievirus VaccinE in Healthy VoluNTteers
Phase 1
Completed
- Conditions
- Viral; Infection, Coxsackie(Virus)
- Interventions
- Biological: PRV-101Other: Placebo
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Provention Bio, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04690426
- Locations
- 🇫🇮
Clinical Research Services Turku (CRST) Oy, Turku, Finland
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects
Phase 1
Completed
- Conditions
- Safety
- Interventions
- Biological: PRV-3279 or placebo
- First Posted Date
- 2019-05-20
- Last Posted Date
- 2023-08-28
- Lead Sponsor
- Provention Bio, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03955666
- Locations
- 🇺🇸
Clinical site, Baltimore, Maryland, United States
Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab
Phase 3
Completed
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Biological: PlaceboBiological: teplizumab
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Provention Bio, Inc.
- Target Recruit Count
- 328
- Registration Number
- NCT03875729
- Locations
- 🇺🇸
Indiana University Hospital and Riley Hospital for Children (Site 014), Indianapolis, Indiana, United States
🇺🇸Benaroya Research Institute at Virginia Mason (Site 016), Seattle, Washington, United States
🇺🇸U. Minnesota Health Clinical Research Unit (Site 031), Minneapolis, Minnesota, United States
Phase 2a Study of PRV-6527 in Subjects With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Provention Bio, Inc.
- Target Recruit Count
- 93
- Registration Number
- NCT03854305
- Locations
- 🇺🇦
Clinical site, Khmelnytskyi, Ukraine
🇺🇦Clinical Site2, Zaporizhzhya, Ukraine
🇺🇦Clinical Site 3, Kyiv, Ukraine
A Study to Evaluate the Safety of PRV-300 in Adult Subjects With Moderately to Severely Active Ulcerative Colitis
Phase 1
Completed
- Conditions
- Ulcerative Colitis
- Interventions
- Biological: PRV-300Biological: Placebo
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2020-02-13
- Lead Sponsor
- Provention Bio, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT03849599
- Locations
- 🇺🇦
Clinical Site, Kapitanivka, Ukraine
© Copyright 2025. All Rights Reserved by MedPath